The therapeutic potential of resveratrol: a review of clinical trials

Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol. Most of the clinical trials of resveratrol have focused on cancer, neurological disorders, cardiovascular diseases, diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity. We found that for neurological disorders, cardiovascular diseases, and diabetes, the current clinical trials show that resveratrol was well tolerated and beneficially influenced disease biomarkers. However resveratrol had ambiguous and sometimes even detrimental effects in certain types of cancers and in NAFLD. In most of the clinical trials, the major obstacle presented was resveratrol’s poor bioavailability. Thus, this work provides useful considerations for the planning and design of future pre-clinical and clinical research on resveratrol.

[1]  T. Walle,et al.  HIGH ABSORPTION BUT VERY LOW BIOAVAILABILITY OF ORAL RESVERATROL IN HUMANS , 2004, Drug Metabolism and Disposition.

[2]  A. Chabowski,et al.  Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials. , 2017, Nutrition.

[3]  J. Auwerx,et al.  Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. , 2011, Cell metabolism.

[4]  P. Belmonte-de-Abreu,et al.  Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors , 2016, Nutrients.

[5]  A. Alayev,et al.  Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer , 2017, Journal of cellular physiology.

[6]  Y. Shukla,et al.  Resveratrol and cellular mechanisms of cancer prevention , 2011, Annals of the New York Academy of Sciences.

[7]  R. Gambino,et al.  Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. , 2013, Current medicinal chemistry.

[8]  Yu Qin,et al.  Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[9]  K. Magyara,et al.  Cardioprotection by resveratrol : A human clinical trial in patients with stable coronary artery disease , 2012 .

[10]  L. Howells,et al.  Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice , 2015, Science Translational Medicine.

[11]  K. Klein,et al.  Resveratrol does not benefit patients with nonalcoholic fatty liver disease. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  P. Farmer,et al.  The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 , 2002, British Journal of Cancer.

[13]  M. Garcia-Conesa,et al.  Resveratrol and Clinical Trials: The Crossroad from In Vitro Studies to Human Evidence , 2013, Current pharmaceutical design.

[14]  M. Trevisan,et al.  Elicitation and accumulation of stilbene phytoalexins in grapevine berries infected by Botrytis cinerea , 2015 .

[15]  A. Hekmatdoost,et al.  Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. , 2014, Nutrition research.

[16]  N. Barzilai,et al.  Pilot study of resveratrol in older adults with impaired glucose tolerance. , 2012, The journals of gerontology. Series A, Biological sciences and medical sciences.

[17]  Norman R. Farnsworth,et al.  Cancer Chemopreventive Activity of Resveratrol, a Natural Product Derived from Grapes , 1997, Science.

[18]  G. Rosner,et al.  A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination , 2015, The Prostate.

[19]  J. Pezzuto Resveratrol as an Inhibitor of Carcinogenesis , 2008 .

[20]  Raymond Scott Turner,et al.  Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease , 2017, Journal of Neuroinflammation.

[21]  James B. Brewer,et al.  A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease , 2015, Neurology.

[22]  P. Elliott,et al.  Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases—Safety, Pharmacokinetics, and Pharmacodynamics , 2011, Cancer Prevention Research.

[23]  W. V. McCarthy,et al.  The re'lationship of resveratrol production to infection of grapevine leaves by Botrytis cinerea , 2016 .

[24]  Sameer S. Kulkarni,et al.  The molecular targets of resveratrol. , 2015, Biochimica et biophysica acta.

[25]  N. Seeram,et al.  Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. , 2004, Anticancer research.

[26]  A. Alayev,et al.  The Combination of Rapamycin and Resveratrol Blocks Autophagy and Induces Apoptosis in Breast Cancer Cells , 2015, Journal of cellular biochemistry.

[27]  Zhiwei Wang,et al.  Cellular signaling perturbation by natural products. , 2009, Cellular signalling.

[28]  A. Alayev,et al.  Resveratrol prevents rapamycin-induced upregulation of autophagy and selectively induces apoptosis in TSC2-deficient cells , 2014, Cell cycle.

[29]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. , 2006, Carcinogenesis.

[30]  S. Radhakrishnan,et al.  Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways , 2010, BMC Cancer.

[31]  S. Hamilton-Dutoit,et al.  Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease , 2016, Scandinavian journal of gastroenterology.

[32]  V. Feigin,et al.  Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2014, The Lancet.

[33]  P. Kopp Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? , 1998, European journal of endocrinology.

[34]  Donald J L Jones,et al.  Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. , 2010, Cancer research.

[35]  G. Rottinghaus,et al.  Trans-Resveratrol Alters Mammary Promoter Hypermethylation in Women at Increased Risk for Breast Cancer , 2012, Nutrition and cancer.

[36]  A. Gescher,et al.  Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4′‐tetramethoxystilbene (DMU‐212) on adenoma development in the ApcMin+ mouse and cyclooxygenase‐2 in human‐derived colon cancer cells , 2005, International journal of cancer.

[37]  Karen L Jones,et al.  Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial. , 2016, The American journal of clinical nutrition.

[38]  J. Crowell,et al.  Phase I Dose Escalation Pharmacokinetic Study in Healthy Volunteers of Resveratrol, a Potential Cancer Chemopreventive Agent , 2007, Cancer Epidemiology Biomarkers & Prevention.

[39]  Y. Yun,et al.  Pterostilbene, a natural dimethylated analog of resveratrol, inhibits rat aortic vascular smooth muscle cell proliferation by blocking Akt-dependent pathway. , 2010, Vascular pharmacology.

[40]  C. Dolea,et al.  World Health Organization , 1949, International Organization.

[41]  W. Wu,et al.  3,3',4,5,5'-Pentahydroxy-trans-stilbene, a resveratrol derivative, induces apoptosis in colorectal carcinoma cells via oxidative stress. , 2010, European journal of pharmacology.

[42]  D. Hougaard,et al.  Resveratrol reduces the levels of circulating androgen precursors but has no effect on, testosterone, dihydrotestosterone, PSA levels or prostate volume. A 4‐month randomised trial in middle‐aged men , 2015, The Prostate.

[43]  The effects of different familial Alzheimer’s disease mutations on APP processing in vivo , 2017, Alzheimer's Research & Therapy.

[44]  Y. Qian,et al.  A combination of isolated phytochemicals and botanical extracts lowers diastolic blood pressure in a randomized controlled trial of hypertensive subjects , 2016, European Journal of Clinical Nutrition.

[45]  P. Elliott,et al.  A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma , 2013, British journal of haematology.

[46]  B. Sümegi,et al.  Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. , 2011, The British journal of nutrition.

[47]  H. Hausenblas,et al.  Resveratrol treatment as an adjunct to pharmacological management in type 2 diabetes mellitus--systematic review and meta-analysis. , 2015, Molecular nutrition & food research.

[48]  Q. Bai,et al.  Resveratrol improves delayed r‐tPA treatment outcome by reducing MMPs , 2016, Acta neurologica Scandinavica.

[49]  L. Motiwale,et al.  Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. , 2011, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[50]  Xiangyi Zheng,et al.  Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo , 2010, Cancer science.

[51]  J. Bhatt,et al.  Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. , 2012, Nutrition research.

[52]  A. Alayev,et al.  Resveratrol as a novel treatment for diseases with mTOR pathway hyperactivation , 2015, Annals of the New York Academy of Sciences.

[53]  Weigang Yuan,et al.  Efficacy of Resveratrol Supplementation against Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Placebo-Controlled Clinical Trials , 2016, PloS one.

[54]  S. Renaud,et al.  Wine, alcohol, platelets, and the French paradox for coronary heart disease , 1992, The Lancet.

[55]  R. Mensink,et al.  Resveratrol Does Not Influence Metabolic Risk Markers Related to Cardiovascular Health in Overweight and Slightly Obese Subjects: A Randomized, Placebo-Controlled Crossover Trial , 2015, PloS one.

[56]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[57]  N. Seiler,et al.  Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. , 2000, Cancer letters.

[58]  A. Reiss,et al.  Resveratrol in cholesterol metabolism and atherosclerosis. , 2012, Journal of medicinal food.

[59]  S. Pervaiz Resveratrol-from the Bottle to the Bedside? , 2001, Leukemia & lymphoma.

[60]  J. Saver,et al.  Improving reperfusion therapy for acute ischaemic stroke , 2011, Journal of thrombosis and haemostasis : JTH.

[61]  T. Walle Bioavailability of resveratrol , 2011, Annals of the New York Academy of Sciences.

[62]  Hongwei Yao,et al.  Regulation of SIRT1 in cellular functions: role of polyphenols. , 2010, Archives of biochemistry and biophysics.

[63]  N. Møller,et al.  High-Dose Resveratrol Supplementation in Obese Men An Investigator-Initiated, Randomized, Placebo-Controlled Clinical Trial of Substrate Metabolism, Insulin Sensitivity, and Body Composition , 2013 .

[64]  Alan D. Lopez,et al.  The Global Burden of Disease Study , 2003 .

[65]  J. Baur,et al.  Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. , 2013, International journal of cardiology.

[66]  Sanghyun Cho,et al.  Cardiovascular Protective Effects and Clinical Applications of Resveratrol. , 2017, Journal of medicinal food.

[67]  G. Pasinetti,et al.  Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment. , 2015, Biochimica et biophysica acta.

[68]  J. K. Kundu,et al.  Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-κB in mouse skin by blocking IκB kinase activity , 2006 .

[69]  M. Garcia-Conesa,et al.  One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. , 2012, The American journal of cardiology.

[70]  B. Bonavida,et al.  Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. , 2004, Molecular cancer therapeutics.

[71]  A. Alayev,et al.  Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. , 2015, American journal of respiratory cell and molecular biology.

[72]  M. Garcia-Conesa,et al.  Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. , 2012, Molecular nutrition & food research.

[73]  A. Alayev,et al.  Phosphoproteomics Reveals Resveratrol-Dependent Inhibition of Akt/mTORC1/S6K1 Signaling , 2014, Journal of proteome research.